Maxwell Biosciences | Anti-infectives against SARS COV-2

Maxwell Biosciences: Biomimetic medicines for SARS COV-2

Maxwell Biosciences, led by CEO Joshua McClure, is working on a peptidomimetic medicine platform that produces low-molecular-weight chemicals that are functionally unique from macromolecules due to their ability to cross membranes easily and can provide breakthrough against SARS COV-2.

These chemicals are intended to cure illness by functionally mimicking human peptides. The National Institute of Allergy and Infectious Diseases (NIAID) has found that Maxwell’s biomimetic medicines are effective against all coronaviruses tested, including SARS CoV2, SARS-1, MERS, and Coronavirus Beta. The CLAROMERTM brand anti-infectives platform generates a diverse library of oligomeric structures that have been shown in preclinical animal studies and electron micrograph imaging of bacterial, viral, and fungal membranes to be well tolerated in animals and to potently disrupt the membranes of a broad spectrum of viruses and other pathogens.

Features:

• Anti-infectives
• High-tissue Tolerance
• Biostability
• High-potency against Pathogens

In short, Maxwell Biosciences is working on the biomimetic cure against all variants of the Corona virus.